William R. Rohn - Chairman
William R. Rohn joined our board of directors as the chairman in connection with Pfenex’s initial public offering in July 2014. Most recently, Mr. Rohn served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. Mr. Rohn also held various management positions with IDEC Pharmaceuticals, a biotechnology company, including: President and Chief Operating Officer from 1998 to 2003, Senior Vice President, Commercial Operations from 1996 to 1998 and Senior Vice President, Commercial and Corporate Development from 1993 to 1996. He also held various management positions with Adria Laboratories, a pharmaceutical company acquired by Pfizer Inc., including: Senior Vice President of Commercial Operations from 1991 to 1993 and Vice President of Business Development and Licensing from 1985 to 1990. Mr. Rohn currently serves on the board of directors of Hansen Medical, Inc., a medical device company. Mr. Rohn previously served on the boards of Intellikine, Inc., a pharmaceutical company acquired by Takeda America Holdings, Inc., Cerus Corporation, a biomedical products company, Elan Corporation, plc, a pharmaceutical company acquired by Perrigo Company plc, Metabasis Therapeutics, Inc., a biopharmaceutical company that merged with Ligand Pharmaceuticals Inc., and Pharmacyclics Inc., a pharmaceutical company. Mr. Rohn holds a Bachelor’s degree in Marketing from Michigan State University and has completed graduate-level coursework in Business Administration at Indiana State University.
Robin D. Campbell, Ph.D.
Dr. Campbell joined our board of directors in September 2014. He has over 25 years of experience in pharmaceutical and biotechnology sales, marketing, product development and general management in both the U.S. and in international markets. Currently he serves as Chairman of the Board of Aptitude Medical Systems, an early stage company creating high performance aptamers for research, diagnostic and therapeutic use. He is also a Lecturer in the Technology Management Program of the College of Engineering at the University of California at Santa Barbara. From 2004 to 2008, Dr. Campbell was President and CEO of Naryx Pharma, a venture-backed specialty pharmaceutical company developing novel, topically delivered treatments for chronic sinusitis and other conditions treatable by intranasal drug delivery. Prior to joining Naryx Pharma, Dr. Campbell was at Amgen from 1989 to 2002, where his most recent position was Vice President and General Manager, U.S. Oncology Business Unit. In this position, he led an integrated team responsible for the marketing, sales and medical development of products generating over $1 billion of annual sales including Neupogen and Neulasta. His professional experience also includes sales, marketing and managerial responsibilities with Ciba-Geigy Corporation from 1984 to 1989. He earned a Bachelor of Arts in Zoology at the University of North Carolina at Chapel Hill, and a Ph.D. in Microbiology and Immunology at the Bowman Gray School of Medicine of Wake Forest University.
James C. Gale
James Gale has served as a member of our board of directors since 2009. Since 1998, Mr. Gale has served as the founding partner and a managing director of Signet Healthcare Partners, a private equity firm that invests in commercial stage healthcare companies, and an affiliate of SMH Capital, Inc. Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC from 1992 to 1998. Prior to joining Gruntal, Mr. Gale originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent from 1989 to 1992. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co., an investment bank. He serves as a member of the board of directors of two public companies, IGI Laboratories, Inc. and Knight Therapeutics Inc., as well as several private companies. During the past five years, he also served on the board of directors of two additional public companies, Paladin Labs Inc. and Octoplus BV. Mr. Gale holds a Bachelor’s degree in Education from the University of Arizona and an M.B.A. from the University of Chicago.
Bertrand C. Liang, M.D., Ph.D., M.B.A.
Bert Liang is the founding and current CEO of Pfenex Inc. He was previously Vice Chairman at Paramount Biosciences, founder, CEO and Chair of Tracon Pharma, founder and Chair of Coronado Biosciences (NASDAQ: CNDO), and Site Head, Vice President, Development and corporate venture capital, at Biogen IDEC, and Global Development Lead at Amgen. Dr. Liang previously held academic positions at the NCI, University of Colorado and University of Vermont. Dr. Liang is an alumnus of Northwestern Medical School, the University of Bolton, University of London, Regis University and the MIT Sloan School of Management, and trained in internal medicine at Brown University, Neurology and Oncology at the University of Michigan, with post-doctoral studies in molecular biology and genetics at the NIH.
Phillip M. Schneider, M.B.A
Phillip M. Schneider joined our board in connection with Pfenex’s initial public offering in July 2014. Most recently, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, from 1987 to 2003, including: Senior Vice President and Chief Financial Officer from 1997 to 2003; and Director of Finance and Administration from 1992 to 1997. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987 and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984, where he attained his CPA license. He currently serves as a member of the board of directors of Arena Pharmaceuticals Corporation, a pharmaceutical company, which he joined in 2008, and Auspex Pharmaceuticals, a pharmaceutical company, which he joined in 2014. He previously served as a member of the board of directors of Gen-Probe, Inc., a biotechnology company, from 2002 to 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California.
Kenneth Van Heel
Kenneth Van Heel joined our board of directors in 2012. Since 2007, Mr. Van Heel has served as Global Director of Portfolio Investments and Director of Dow Chemical Canada Pension Plan at The Dow Chemical Company, a chemicals manufacturer, and has held various positions with Dow and its wholly-owned subsidiaries, including: Senior Manager of Private Equity of The Dow Chemical Company from 2003 to 2006, Manager of Dow Corporate Venture Capital from 2000 until 2003 and other various positions with Dow since 1994. Mr. Van Heel holds a Bachelor’s degree in Materials Science and Engineering from Illinois Institute of Technology and an M.B.A. from DePaul University.